Tests orforglipron for weight management in children with obesity or overweight
Tests orforglipron against placebo in children aged 6 to 17 with obesity or overweight.
Plain-language title generated from the registry record
Registry title: A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Key facts
- Where
- Barcelona, Madrid, Málaga, Sabadell, Seville, and Vitoria-Gasteiz, SpainSee the 6 sites
- Phase
- Phase 3
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with obesity, or with overweight and a weight-related health problem, who have already tried a lifestyle program without enough weight loss.
- Age
- 6 to 17 years.
- Sex
- All sexes can join.
- Disease stage
- Obesity: BMI at or above the 95th percentile for age and sex. Overweight: BMI at or above the 85th but below the 95th percentile, plus at least 1 weight-related condition such as hypertension, type 2 diabetes, prediabetes, dyslipidemia, obstructive sleep apnea, MASH or MASLD.
- Earlier treatment
- At least 1 unsuccessful effort to lose weight after a structured lifestyle program (diet and exercise counseling for at least 3 months).
Main reasons for not taking part
- Weight reduction surgery or procedure, done or planned during the study
- A secondary cause of obesity, such as hypothalamic, monogenetic, syndromic or endocrine causes
- Weight loss of more than 5 kg (11 lbs) in the 90 days before screening
- Type 1 diabetes, or history of ketoacidosis or hyperosmolar state, or HbA1c above 9.0% (75 mmol/mol)
- Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 17 years old?
Source: NCT06672549, who can take part
Where in Spain
- Hospital Universitario Vall d'HebronBarcelona, SpainNot yet recruiting
- Hospital Infantil Universitario Nino JesusMadrid, SpainNot yet recruiting
- Hospital Regional Universitario de Malaga - Hospital Materno-InfantilMálaga, SpainNot yet recruiting
- Corporacio Sanitaria Parc TauliSabadell, SpainNot yet recruiting
- Instituto Hispalense de PediatriaSeville, SpainNot yet recruiting
- Hospital Universitario de Araba (HUA)- Hospital TxagorritxuVitoria-Gasteiz, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT06672549
- Record updated
- 4 November 2026
- Original description
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.Read full original descriptionShow less
A Master Protocol for a Randomized, Controlled, Clinical Platform Trial to Investigate the Efficacy and Safety of Interventions for Chronic Weight Management in Pediatric Participants With Obesity or Overweight
The purpose of this pediatric, chronic weight management, Phase 3 Master Protocol (PWMP) is to create a framework to evaluate the safety and efficacy of pharmacologic agents for the treatment of obesity or overweight in pediatric participants.
Inclusion: Have a history of at least 1 unsuccessful effort to lose sufficient body weight after participation in a structured lifestyle modification program (diet and exercise counseling for at least 3 months) prior to screening; Obesity as defined by BMI equal to or above the 95th percentile for age and sex (on age- and gender-specific growth chart [CDC-NCHS, 2022]); OR; Applies to participant age between 12 and <18 years old. Overweight as defined by BMI equal to or above the 85th percentile but less than the 95th percentile for age and sex, on age- and sex-specific growth chart (CDC-NCHS, 2022), and at least 1 weight-related comorbidity,; hypertension; type 2 diabetes (T2D); prediabetes; dyslipidemia; obstructive sleep apnea; metabolic dysfunction-associated steatohepatitis (MASH) or metabolic dysfunction-associated steatotic liver disease (MASLD).
Exclusion: Have undergone or plan to undergo weight reduction procedure during the study, such as, but not limited to:; gastric bypass; sleeve gastrectomy; restrictive bariatric surgery, such as Lap-Band® gastric banding, or; any other procedure intended to result in weight reduction; Have a self-reported, or by parent or legal guardian where applicable, decrease in body weight greater than 5 kg (11 lbs) within 90 days before screening irrespective of medical records; Have a diagnosis that is a secondary cause of obesity or have a history of abrupt onset of obesity suggesting a secondary cause, such as hypothalamic, monogenetic, syndromic, or endocrine causes; Have type 1 diabetes or history of ketoacidosis, or hyperosmolar state; Have a family or personal history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2; Have HbA1c >9.0% (75 mmol/mol) as measured by central laboratory at screening.